{"id":50936,"date":"2022-11-16T13:02:20","date_gmt":"2022-11-16T12:02:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/"},"modified":"2022-11-16T13:02:20","modified_gmt":"2022-11-16T12:02:20","slug":"choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/","title":{"rendered":"Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4989023\/choroideremia-pipeline-insight-2022?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=9bqmjs&amp;utm_campaign=1776765+-+Choroideremia+Drug+Pipeline+Insights+Report+2022+Featuring+Spark+Therapeutics%2C+Molecular+Therapeutics%2C+Curative+Biotechnology%2C+%26+Ray+Therapeutics&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Choroideremia &#8211; Pipeline Insight, 2022&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221116005576\/en\/1639561\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221116005576\/en\/1639561\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Choroideremia pipeline landscape.\n<\/p>\n<p>\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n<p>\nThe report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Choroideremia pipeline landscape is provided which includes the disease overview and Choroideremia treatment guidelines. The assessment part of the report embraces, in depth Choroideremia commercial assessment and clinical assessment of the pipeline products under development.\n<\/p>\n<p>\nIn the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Choroideremia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.\n<\/p>\n<p>\n<strong>Report Highlights<\/strong>\n<\/p>\n<p>\nThe companies and academics are working to assess challenges and seek opportunities that could influence R&amp;D Choroideremia. The therapies under development are focused on novel approaches to treat\/improve Choroideremia.\n<\/p>\n<p>\nIn February 2019, Roche entered into a definitive merger agreement to acquire Spark Therapeutics and its clinical assets, including SPK-7001 for choroideremia in Phase I\/II.\n<\/p>\n<p>\n4D therapeutics is developing and investigating its lead product candidate 4D-110 in an ongoing Phase I dose-escalation clinical trial in patients with choroideremia related to mutations in the CHM gene.\n<\/p>\n<p>\n<strong>Choroideremia Emerging Drugs<\/strong>\n<\/p>\n<p>\nAAV2-hCHM: Spark Therapeutics\n<\/p>\n<p>\nSpark Therapeutics is advancing an open-label, dose-escalating Phase I\/II trial designed to assess the safety and preliminary efficacy of subretinal administration of investigational SPK-7001. Each of the investigational research programs uses an adeno-associated viral (AAV) vector developed and manufactured by the Spark team and their collaborators.\n<\/p>\n<p>\n<strong>Choroideremia: Therapeutic Assessment<\/strong>\n<\/p>\n<p>\nThis segment of the report provides insights about the Choroideremia drugs segregated based on following parameters that define the scope of the report, such as:\n<\/p>\n<p>\n<strong>Major Players in Choroideremia<\/strong>\n<\/p>\n<p>\nThere are approx. 5+ key companies which are developing the therapies Choroideremia. The companies which have their Choroideremia drug candidates in the most advanced stage, i.e phase I\/II include Spark Therapeutics\n<\/p>\n<p>\n<strong>Phases<\/strong>\n<\/p>\n<p>\n<strong>This report covers around 5+ products under different phases of clinical development like<\/strong>\n<\/p>\n<ul>\n<li>\nLate stage products (Phase III)\n<\/li>\n<li>\nMid-stage products (Phase II)\n<\/li>\n<li>\nEarly-stage product (Phase I) along with the details of\n<\/li>\n<li>\nPre-clinical and Discovery stage candidates\n<\/li>\n<li>\nDiscontinued &amp; Inactive candidates\n<\/li>\n<li>\nRoute of Administration\n<\/li>\n<\/ul>\n<p>\n<strong>Choroideremia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.<\/strong>\n<\/p>\n<p>\n<strong>Products have been categorized under various ROAs such as<\/strong>\n<\/p>\n<ul>\n<li>\nOral\n<\/li>\n<li>\nIntravenous\n<\/li>\n<li>\nSubcutaneous\n<\/li>\n<li>\nMolecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>Products have been categorized under various Molecule types such as<\/strong>\n<\/p>\n<ul>\n<li>\nSmall molecule\n<\/li>\n<li>\nCell Therapy\n<\/li>\n<li>\nPeptides\n<\/li>\n<li>\nPolymer\n<\/li>\n<li>\nSmall molecule\n<\/li>\n<li>\nGene therapy\n<\/li>\n<li>\nProduct Type\n<\/li>\n<\/ul>\n<p>\nDrugs have been categorized under various product types like Mono, Combination and Mono\/Combination.\n<\/p>\n<p>\n<strong>Choroideremia: Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Choroideremia therapeutic drugs key players involved in developing key drugs.\n<\/p>\n<p>\n<strong>Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Choroideremia drugs.\n<\/p>\n<p>\n<strong>Choroideremia Report Insights<\/strong>\n<\/p>\n<ul>\n<li>\nChoroideremia Analysis\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<li>\nImpact of Drugs\n<\/li>\n<\/ul>\n<p>\n<strong>Choroideremia Report Assessment<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Product Profiles\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nPipeline Assessment\n<\/li>\n<li>\nInactive drugs assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Questions<\/strong>\n<\/p>\n<p>\n<strong>Current Treatment Scenario and Emerging Therapies:<\/strong>\n<\/p>\n<ul>\n<li>\nHow many companies are developing Choroideremia drugs?\n<\/li>\n<li>\nHow many Choroideremia drugs are developed by each company?\n<\/li>\n<li>\nHow many emerging drugs are in mid-stage, and late-stage of development for the treatment of Choroideremia?\n<\/li>\n<li>\nWhat are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Choroideremia therapeutics?\n<\/li>\n<li>\nWhat are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?\n<\/li>\n<li>\nWhat are the clinical studies going on for Choroideremia and their status?\n<\/li>\n<li>\nWhat are the key designations that have been granted to the emerging drugs?\n<\/li>\n<\/ul>\n<p>\n<strong>Key Players<\/strong>\n<\/p>\n<ul>\n<li>\nSpark Therapeutics\n<\/li>\n<li>\nMolecular Therapeutics\n<\/li>\n<li>\nCurative Biotechnology\n<\/li>\n<li>\nRay Therapeutics\n<\/li>\n<\/ul>\n<p>\n<strong>Key Products<\/strong>\n<\/p>\n<ul>\n<li>\nAAV2-hCHM\n<\/li>\n<li>\n4D 110\n<\/li>\n<li>\nMetformin\n<\/li>\n<li>\nRAY 001\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4989023\/choroideremia-pipeline-insight-2022?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=9bqmjs&amp;utm_campaign=1776765+-+Choroideremia+Drug+Pipeline+Insights+Report+2022+Featuring+Spark+Therapeutics%2C+Molecular+Therapeutics%2C+Curative+Biotechnology%2C+%26+Ray+Therapeutics&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/suln3y<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;a&#x69;l&#x74;o&#x3a;p&#x72;e&#x73;s&#x40;&#114;&#x65;&#115;&#x65;&#97;&#x72;&#99;&#x68;&#97;&#x6e;&#100;&#x6d;&#97;r&#x6b;e&#x74;s&#x2e;c&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x65;&#x73;&#x73;&#x40;&#x72;&#x65;&#x73;&#x65;&#x61;&#x72;&#x63;&#x68;&#x61;&#x6e;&#x64;&#x6d;&#x61;&#x72;&#x6b;&#x65;&#x74;&#x73;&#x2e;&#x63;&#x6f;&#x6d;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Choroideremia &#8211; Pipeline Insight, 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Choroideremia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50936","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Choroideremia &#8211; Pipeline Insight, 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Choroideremia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-16T12:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221116005576\/en\/1639561\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-11-16T12:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/\"},\"wordCount\":756,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005576\\\/en\\\/1639561\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/\",\"name\":\"Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005576\\\/en\\\/1639561\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-11-16T12:02:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005576\\\/en\\\/1639561\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221116005576\\\/en\\\/1639561\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Choroideremia &#8211; Pipeline Insight, 2022&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Choroideremia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-16T12:02:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221116005576\/en\/1639561\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics &#8211; ResearchAndMarkets.com","datePublished":"2022-11-16T12:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/"},"wordCount":756,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221116005576\/en\/1639561\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/","name":"Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221116005576\/en\/1639561\/21\/logo.jpg","datePublished":"2022-11-16T12:02:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221116005576\/en\/1639561\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221116005576\/en\/1639561\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/choroideremia-drug-pipeline-insights-report-2022-featuring-spark-therapeutics-molecular-therapeutics-curative-biotechnology-ray-therapeutics-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, &amp; Ray Therapeutics &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50936"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50936\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}